Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India.
Endocr Metab Immune Disord Drug Targets. 2024;24(5):549-561. doi: 10.2174/0118715303256582230919093535.
Due to insulin resistance and excessive blood sugar levels, type 1 diabetes mellitus (T1DM) is characterized by pancreatic cell loss. This condition affects young people at a higher rate than any other chronic autoimmune disease. Regardless of the method, exogenous insulin cannot substitute for insulin produced by a healthy pancreas. An emerging area of medicine is pancreatic and islet transplantation for type 1 diabetics to restore normal blood sugar regulation. However, there are still obstacles standing in the way of the widespread use of these therapies, including very low availability of pancreatic and islets supplied from human organ donors, challenging transplantation conditions, high expenses, and a lack of easily accessible methods. Efforts to improve Type 1 Diabetes treatment have been conducted in response to the disease's increasing prevalence. Type 1 diabetes may one day be treated with stem cell treatment. Stem cell therapy has proven to be an effective treatment for type 1 diabetes. Recent progress in stem cell-based diabetes treatment is summarised, and the authors show how to isolate insulin-producing cells (IPCs) from a variety of progenitor cells.
由于胰岛素抵抗和血糖水平过高，1 型糖尿病（T1DM）的特征是胰腺细胞丧失。这种情况在年轻人中的发病率高于任何其他慢性自身免疫性疾病。无论采用何种方法，外源性胰岛素都不能替代健康胰腺产生的胰岛素。医学的一个新兴领域是对 1 型糖尿病患者进行胰腺和胰岛移植，以恢复正常的血糖调节。然而，这些疗法的广泛应用仍然存在障碍，包括人类器官供体提供的胰腺和胰岛非常稀缺、移植条件具有挑战性、费用高昂，以及缺乏易于获取的方法。为了改善 1 型糖尿病的治疗，人们针对该疾病的发病率不断上升做出了努力。有朝一日，干细胞治疗可能会用于治疗 1 型糖尿病。干细胞疗法已被证明对 1 型糖尿病有效。本文总结了基于干细胞的糖尿病治疗的最新进展，并展示了如何从各种祖细胞中分离出产生胰岛素的细胞（IPCs）。
